Conclusion: Recent large scale genomic studies have started to elucidate how genetic variation affects variation in the ANM and importantly has informed functional experiments targeting specific molecular players for pharmacological or life-style treatments. Following the example of other complex traits, larger cohorts are anticipated to expand...

Conclusion: A small percentage of cervical cancer survivors have adequate information about menopause and HRT, and a smaller proportion receive hormone replacement therapy. These data show the need for attention to these young women who have menopause arising from treatment, and reinforce the importance for survivorship guidelines for cervical...

Conclusion: ß-Glucuronidase enzyme activity, upon which polyphenol health-related benefits may depend, is not associated with menopausal status. Future studies are required to determine clinical significance and mechanisms driving ß-glucuronidase associations with ethnicity, inflammation, and adiposity in women.

Conclusion: Despite all the advances in considering the best options to treat menopause-induced HFpEF, which involves the reduction of cardioprotection due to estrogen depletion, the focus should be the modulation of the RAS and sympathetic system. The combination of the alternatives described and lifestyle changes including physical activity...

Conclusion: OAB symptoms are highly prevalent across adult women, including the oldest old, who are often excluded from treatment trials. Despite interest in vitamin D supplementation as a low-cost strategy to address OAB, our findings indicate oral vitamin D is not associated with prevalent OAB in middle-aged and older women.